Buy

Happy Forgings’ (HFL)’s Q1FY26 performance was broadly in line with our estimates. HFL continued to outperform peers in Q1. While PV / industrial / domestic farm segment continues to do well, domestic CV may likely pick up going ahead.

Grasim Industries (Grasim) has kicked-off FY26 on a strong footing. Its standalone entity’s (SA) Q1FY26 EBITDA has not only beat our estimate (at INR 3.85bn, up 18% YoY; I-Sec: INR 2.55bn), revenues of the new business segments (paints/B2B ecommerce) too have pleasantly surprised; also, EBITDA losses are in check.

Akums Drugs and Pharmaceuticals (Akums)’s Q1FY26 revenue was muted due to slowdown across verticals; however, better product mix aided gross margin expansion (+170bps YoY).

Below our estimate (mainly losses at Cayman Integrated Healthcare), Narayana Hrudayalaya’s Q1 EBITDA was Rs3.4bn, up 11% y/y, 7% q/q.

The cost-to-income ratio in Q1FY26 inched up mainly due to a one-time actuarial PAT grew modestly by 12.1% YoY to Rs. 224 cr in Q1FY26, despite an uptick in Asset quality experienced slight deterioration, with GNPA/NNPA rising to 0.98%/0.54% from 0.91%/0.49% in Q1FY25. The Provision Coverage Ratio (PCR)...

Repco Home Finance's AUM growth remain stable at 7% YoY vs 7% YoY (FY25) backed by 22%YoY growth in disbursements. Further, management guided for AUM of Rs.16bn by FY26, and aspires to touch loan book of Rs.250bn by FY28. Disbursements is expected to be Rs.40bn in FY26, with the non-Tamil Nadu states equally contributing to the overall numbers. NIMs remain stable at 5.2% led by decline in cost of funds. Asset quality remain stable during the quarter with GNPA at 3.3% vs 3.3% QoQ backed by higher write offs. NII grew by 10% YoY led by improvement in NIMs. PAT grew by 2% YoY led by lower non-interest income. Thus,...

We maintain our BUY rating on the stock with a target price of Rs 380/share, implying an 11% upside potential from the CMP.

We maintain a BUY rating on Medanta, supported by the expected recovery from temporary business disruptions, improvement in ARPOB, and incremental bed capacity addition, including the Noida hospital, which is likely to be operational by the end of H1FY26E.

We maintain our BUY recommendation on the stock.

We maintain our BUY rating.